Note: Descriptions are shown in the official language in which they were submitted.
CA 02282757 1999-09-O1
WO 98/39015 PCT/SE98/00401
1
Ophthalmic composition
The present invention relates to an ophthalmic composi-
tion for use in ocular surgery and a method for conducting
ocular surgery. In particular the invention relates to a
composition of sodium hyaluronate with a specifically de-
fined molecular mass and concentration, for use in ocular
surgery.
Intraocular lens implantation has today become routine
surgery. A major tool to accomplish this was the introduc-
tion of Healon~(1980), the high molecular mass, viscoelas-
tic, noninflammatory preparation of sodium hyaluronate.
Since then the cataract surgery has undergone a tremendous
progress and many viscoelastic products have been devel-
oped. Typically these products are aqueous solutions con-
staining a polysaccharide such as sodium hyaluronate, sodium
chondroitin sulfate and hydroxypropylmethylcellulose, at
concentrations varying from 10-70 mg/ml. The molecular mass
(expressed as mass average relative molecular mass,<M>r,M)
varies from about 20.000 (chondroitin sulfate) to about
5.000.000 (sodium hyaluronate).
A cataract surgery of today can be divided into several
steps. The first step is pupil dilatation and local anaes-
thesia. The operation starts by making an incision into the
anterior chamber of the eye. When the eye is punctured, the
aqueous humour leaks out and the anterior chamber becomes
shallow. A viscoelastic product is injected into the ante-
rior chamber, which then regains its former shape and
depth. The viscoelastic product maintains the anterior
chamber and protects the vulnerable tissues especially the
3o endothelial cells on the cornea.
The next step is to make a hole in the anterior lens
capsule, a capsulotomy, which can be done in several ways.
The viscoelastic helps the surgeon by creating enough space
by maintaining the anterior chamber depth and to stabilize
the lens.
Extraction of the lens nucleus can be done in different
ways, e.g. planned ECCE (extracapsular cataract extrac-
CA 02282757 1999-09-O1
WO 98/39015 PCT/SE98/00401
2
tion) or phacoemulsification (phaco) using ultrasound. The
remaining lens cortex is removed by irrigation/aspiration. -
After removal of the lens, viscoelastic product is
again injected to inflate the capsular bag and to deepen
the anterior chamber to make space for the intraocular lens
implantation. The viscoelastic product maintains the space
in the anterior chamber and is a very important protector
of the endothelial cells and of other intraocular tissues
from direct contact with the lens.
Upon completion of surgery the viscoelastic product is
removed from the eye by irrigation/aspiration and substi-
tuted by physiological salt solution. If needed the wound
is'sutured. "'
Planned ECCE is the term normally used when the lens
'nucleus is removed in one piece. Planned ECCE requires an
incision size of 9 -12 mm.
In the method by phaco the lens nucleus is disinte-
grated with the help of ultrasound and is aspirated through
a small incision, usually approximately 3 mm. An intraocu-
lar lens, foldable or not foldable, is then implanted
through the incision. Phaco is the most modern method,
which has increased rapidly in popularity due to the im-
proved patient outcome. The small incision needed, reduces
the amount of astigmatism induced by the surgery. Phaco is
the most commonly employed technique in most countries and
it will be the dominating technique for the foreseeable fu-
ture.
The demands on the viscoelastic products used in the
surgical steps mentioned above are different. Current vis-
coelastic products can be divided into two broad groups.
The first is a group of highly viscous cohesive products
containing high molecular mass polysaccharides that already
at moderate concentrations (about 1 mg/ml) form flexible
entangled molecular network and which have a high zero-
shear viscosity. The second group consists of lower zero-
shear viscosity dispersive products containing low molecu-
lar mass polysaccharides in high (about 70 mg/ml) concen-
trations, which tend to disperse in the eye and which do
26468-147(S)
CA 02282757 2002-11-29
3
not exhibit cohesive properties even at high concentra-
tions. _
The dispersive products typically contain high concentra-
tion (approximately. 70 mg/ml) of low molecular mass poly-
saccharides (average mass average relative molecular mass
about 200 000). These products fracture easily and stay in
the anterior chamber during the turbulent phacoemulsifica-
tion procedure. However, these products have poor space
maintaining properties. Furthermore, these products car_ not
to easily be removed from the anterior chamber at close of
surgery, and frequently require high pressure to expel from
the syringe through an ophthalmic cannula into the anterior
chamber.
The cohesive products contain high molecular mass poly-
'saccharide (mass average relative molecular mass: 1 to 5
million) at low concentration (10-15 mg/ml). The latter
products can easily be injected through thin cannulas, and
exhibit good space-maintaining properties. They can also
easily be extracted from the anterior chamber due to the
2o cohesive properties. However, as a consequence of the cohe-
sive properties these products frequently leaves the cham-
ber as a chunk during the turbulent phacoemulsification
procedure.
The cohesive viscoelastic products are used to displace
and stabilize tissues and to pressurize the anterior cham-
ber. However, there is a risk that they leave the eye too
quickly during phaco and leave the endothelium not well
protected. On the contrary, the dispersive viscoelastic
products stay in the anterior chamber during phaco but do
not stabilize tissues very well. So far none of the viscoe-
lastic products available have been able to match all vis-
coelastic needs during cataract surgery with phacoemulsifi-
cation and it has been assumed impossible to make such a
product.
To achieve the optimal viscoelastic effect in all the
surgical steps US 5,273,056 suggests to use different vis-
coelastic products in the various steps. US 5,273,056 uses
a combinaticn of both cohesive and disper5ive viscoelastic
CA 02282757 2002-11-29
26468-147(S)
4
products. A similar solution has been suggested by Dr.
Steve A. Arshinoff in the description of the "soft-shell"
technique (Ocular Surgery News, International edition, vol.
14 no. 18 1996, p. 17, "Soft-shell" technique uses two types
of viscoelastic products" reported by Harvey Black).
The present invention provides an improved
ophthalmic composition for use in ocular surgery. Further,
the present invention provides a viscoelastic product that
can be used in all steps of cataract surgery, especially
cataract surgery with phacoemulsification. The present
invention also provides a viscoelastic product which
combines dispersive and cohesive qualities. Yet further,
the invention provides for the use of the compositions of
the invention in ocular surgery. The invention also
provides a commercial package comprising the compositions of
the invention and associated therewith instructions for use
of the compositions in ocular surgery.
According to the present invention an ophthalmic
composition for use in ocular surgery is obtained. The
composition comprises an aqueous solution of sodium
hyaluronate with a concentration within the range of 18 - 40
mg sodium hyaluronate/ml solution and the molecular mass of
sodium hyaluronate being in the range of 1x106 - 10x106
<M>r M.
According to the present invention there is also
provided an ophthalmic composition for use in ocular
surgery, comprising an aqueous solution of sodium
hyaluronate with a concentration within the range of 18 - 40
mg sodium hyaluronate/ml of solution wherein the molecular
mass of the sodium hyaluronate is in the range of 2.5x106 -
1Ox106 <M>r,M, and phosphate as a buffering agent , wherein
said composition is both cohesive and dispersive.
CA 02282757 2002-11-29
26468-147(S)
4a
According to a further aspect of the invention use
of an aqueous solution of sodium hyaluronate with a
concentration within the range of 18 - 40 mg sodium
hyaluronate/ml solution and the molecular mass of sodium
hyaluronate being in the range of 1x106 - 10x106 <M>r,M, for
the manufacture of a composition for ocular surgery is
obtained. The invention also provides for the manufacture
of a composition for ocular surgery using the aqueous
solution described in the previous paragraph.
According to yet a further aspect of the invention
a method for conducting ocular surgery is obtained.
According to the method a composition comprising an aqueous
solution of sodium hyaluronate with a concentration within
the range of 18 - 40 mg sodium hyaluronate/ml solution and
the molecular mass of sodium hyaluronate being in the range
of 1x106 - 10x106 <M>r,M is introduced into the eye as a
surgical aid.
CA 02282757 1999-09-O1
WO 98/39015 PCT/SE98/00401
According to yet a further aspect of the invention a
method for conducting cataract surgery in an eye having an -
anterior chamber, a posterior chamber and a lens capsule is
obtained. The method comprises the following steps:
5 a) entering the anterior chamber by making an incision
and injecting a composition comprising an aqueous solution
of sodium hyaluronate with a molecular mass within the
range of 1x106 - 10x106 <M>r~M and a concentration within
the range of 18-40 mg/ml into the anterior chamber;
b) performing a capsulotomy;
c) removing of lens and lens cortex;
d) injecting into the lens capsule the composition used
in step a) and implanting an intraocular lens;
e) optionally, removing the composition injected in
' steps a) and d) .
With the present invention it was surprisingly found
that the composition according to the invention, with the
increased concentration of the high molecular mass sodium
hyaluronate, had an excellent performance in all steps of
ocular surgery. The new hyaluronate composition is both co-
hesive and dispersive and stays in the anterior chamber
during phaco emulsification. Because of these specific
qualities the composition has a very good protecting effect
against, as well mechanical damage, as against the free
radicals which are formed by the ultrasound during the pha-
coemulsification procedure. The composition is also cohe-
sive enough to maintain the anterior depth. The fact that
the composition works well during the phacoemulsification
step is surprising considering this composition is more co-
3o hesive than known sodium hyaluronate products on the mar-
ket. A possible explanation to the obtained result is that
by making the solution more cohesive, apparently a state is
reached where the solution also becomes brittle. In highly
turbulent flow (as during phaco), the solution close to the
phaco instrument fractures, while a substantial amount of
solution remains in the anterior chamber as a soft shell.
The ophthalmic composition according to the invention
has preferably a concentration within the range of 18 - 35
CA 02282757 1999-09-O1
WO 98/39015 PCT/SE98/00401
6
mg/ml, most preferably within 20 - 28 mg/ml and the molecu-
lar mass of the sodium hyaluronate is preferably within the-
range 1x106 - 6x106 <M>r,M, most preferably within,2.5x106
- 5x106 <M>r,M,.
The ophthalmic composition according to the invention
can be used in all types of ocular surgery, such as cata-
ract surgery, glaucoma surgery, vitreous surgery and poste-
rior segment surgery. The cohesive qualities of the present
composition are very suitable in glaucoma, vitreous and
l0 posterior segment surgery both as a protector of eye tissue
and to move and hold tissue away from the operation area
and as an antiadherence product. However, the composition
is especially suitable for cataract surgery with phacoemul-
sification. Thus, in a preferred embodiment of the present
invention step c) in the above mentioned method is made by
phacoemulsification. At the end of the surgery the composi-
tion according to the invention is preferably removed from
the eye, but can be left in special cases.
The composition according to the invention is prepared
in a conventional manner by dissolving the sodium hyaluro-
nate in an aqueous solvent containing physiological amounts
of sodium chloride to the required concentration of sodium
hyaluronate. Sodium hyaluronate of suitable molecular mass
is today a commercially available product. The solvent may
also contain other inorganic salts such as calcium-, magne-
sium- and potassium chloride in physiological concentra-
tions. Suitably the solvent may also contain buffering
agents such as phosphate, acetate, carbonate or citrate in
physiological concentrations. The solvent may also contain
other physiological compounds. As mentioned above the com-
position has a good protecting effect against the free
radicals produced during phaco. In order to increase this
protective effect a compound acting as a scavenger can be
added to the composition. As suitable scavengers can be
mentioned superoxidedismutase (SOD), mannitol, glutathione
or other known scavanger compounds acceptable to the eye.
CA 02282757 1999-09-O1
WO 98/39015 PCT/SE98/00401
7
The invention will now be illustrated with the follow-
ing examples which however, are not intended to restrict -
the invention.
Example 1:
Two sodium hyaluronate solutions A and B were prepared
accordingly:
Solution A
Sodium hyaluronate <M>r~M = 3x106 20 mg
Sodium chloride 8,5 mg
to Disodium phosphatedihydrate 0,28 mg
Monosodium phosphatemonohydrate 40 ~.g
Water suitable for injection
solutions to obtain 1 ml
pH = 7.0-7.5
Solution B
Sodium hyaluronate <M>r~M = 3x106 25 mg
Sodium chloride 8,5 mg
Disodium phosphatedihydrate 0,28 mg
Monosodium phosphatemonohydrate 40 ug
Water suitable for injection
solutions to obtain 1 ml
pH = 7.0-7.5
These compositions were compared with the following
commercially available products:
Viscoat0 (Alcon Surgical Inc.):
Composition according to the manufacturer:
Sodium chondroitin sulfate 40 mg/ml
<M>r~M = 25000
Sodium hyaluronate 30 mg/ml
<M>r~M = 500.000
pH = 6.2-7.8
CA 02282757 1999-09-O1
WO 98/39015 PCT/SE98/00401
8
Amvisc Plus~ (Chiron Vision):
Composition according to the manufacturer:
Sodium hyaluronate 16 mg/ml
<M>r~M -- 1.5x106
pH = 6.4 (non-buffered)
HealonGV~ (Pharmacies & Upjohn):
Composition according to the manufacturer:
Sodium hyaluronate 14 mg.~ml
<M>r~M = 5x106
pH = 7.0-7.5
Ocucoat~ (Storz Ophthalmics,Inc.):
Composition according to the manufacturer:
Hydroxypropylmethylcellulose 20 mg/ml
<M>r~M = 80.000
pH = 6.8-7.5
The solutions were tinted by fluorescein and filled in sy-
ringes. The materials were tested by an in-house excellent
lab. technician and seven skilled ophthalmic surgeons, in
masked trials, on pig and human cadaver eyes. The perform-
ance of all products in the different surgical steps and
the overall assessment were established on a scale 0 - 100
where 0 = worthless, 100 = excellent:
CA 02282757 1999-09-O1
WO 9$139015 PCT/SE98/00401
9
Step Viscoat Amvisc HealonGV Solution Ocucoat
Solution
Plus B A
Injecti 16 93 93 74 85 80
on
Capsulo 70 56 79 93 83 33
rhexis
Phaco 66 47 21 82 66 17
IOL* 66 73 96 91 98 25
Removal 21 51 93 65 86 20
Overall 42 45 59 86 88 ~ 30
. *lntra
ocular
lens implantation
The result can be visualized the following
also in way,
where denotes better than average worse than aver-
+ and -
age:
Injecti Capsulo Phaco IOL Removal Overall
on rhexis
Viscoat - + + + -
Ocucoat + - - - _ _
Amvisc + + - + + -
plus
Healon + + - + + +
GV
Solutio + + + + + +
n A
Solutio + + + + + +
n B
CA 02282757 1999-09-O1
WO 98/39015 PCT/SE98/00401
From the result it is evident that both solution A and
B according to the invention exhibit a very satisfactory -
performance in all steps of surgery.
5 Example 2:
Further sodium hyaluronate solutions according to the
invention were prepared in the same manner as in example 1
with different molecular mass and concentrations. The solu-
tions were tested by the skilled lab. technician or a
10 skilled ophthalmic surgeon. The following overall assess-
ment was obtained:
Solution Concentration <M>r~M Overall
(mg/ml) (106) assessment
Solution C 18 3.5 85
Solution D 19 1 100
Solution E 19 2 100
Solution F 35 1 100
From these result it is evident that other sodium
hyaluronate solutions within the claimed range work equally
well.
